Skip to main content
NCBI home page
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1996 Mar;34(3):707–713. doi: 10.1128/jcm.34.3.707-713.1996

Immune response to hepatitis A virus capsid proteins after infection.

C H Wang 1, S Y Tschen 1, U Heinricy 1, M Weber 1, B Flehmig 1
PMCID: PMC228874  PMID: 8904442

Abstract

This study was undertaken to determine the immune response of humans to viral capsid polypeptides of hepatitis A virus (HAV) after natural infection, which is very important for vaccine development. Antiviral capsids in 73 serum samples from patients with acute and chronic HAV infections were analyzed by immunoblotting against individual HAV capsid polypeptides (VP1, VP2, VP3, and VP4) by using a cell culture-based HAV antigen. For reference, total anti-HAV immunoglobulin G (IgG) and anti-HAV IgM were also determined by radioimmunoassay. As a result, a dominant immune response against VP1 (98% IgG, 94% IgM) was found in the acute phase. However, many other sera also reacted with VP0 (88% IgG; 35% IgM) and VP3 (81% IgG and 29% IgM). In contrast to the acute phase, anti-VP1, anti-VP0, and anti-VP3, IgG antibodies against all three viral proteins (29, 29, and 73% respectively), especially those against VP3, were found years after onset of HAV disease and over long periods in the sera of hepatitis patients. These results suggest that antibodies for capsid polypeptides are present over an extended period in the sera of HAV-infected patients. They are likely of importance in maintaining long-term immunity.

Full Text

The Full Text of this article is available as a PDF (425.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. André F. E., Hepburn A., D'Hondt E. Inactivated candidate vaccines for hepatitis A. Prog Med Virol. 1990;37:72–95. [PubMed] [Google Scholar]
  2. Bradley D. W., Maynard J. E., Hindman S. H., Hornbeck C. L., Fields H. A., McCaustland K. A., Cook E. H., Jr Serodiagnosis of viral hepatitis A: detection of acute-phase immunoglobulin M anti-hepatitis A virus by radioimmunoassay. J Clin Microbiol. 1977 May;5(5):521–530. doi: 10.1128/jcm.5.5.521-530.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Celis E., Kato I., Miller R. W., Chang T. W. Regulation of the human immune response to HBsAg: effects of antibodies and antigen conformation in the stimulation of helper T cells by HBsAg. Hepatology. 1985 Sep-Oct;5(5):744–751. doi: 10.1002/hep.1840050507. [DOI] [PubMed] [Google Scholar]
  4. Cohen J. I. Hepatitis A virus: insights from molecular biology. Hepatology. 1989 Jun;9(6):889–895. doi: 10.1002/hep.1840090617. [DOI] [PubMed] [Google Scholar]
  5. Farci P., Alter H. J., Govindarajan S., Wong D. C., Engle R., Lesniewski R. R., Mushahwar I. K., Desai S. M., Miller R. H., Ogata N. Lack of protective immunity against reinfection with hepatitis C virus. Science. 1992 Oct 2;258(5079):135–140. doi: 10.1126/science.1279801. [DOI] [PubMed] [Google Scholar]
  6. Flehmig B., Heinricy U., Pfisterer M. Immunogenicity of a killed hepatitis A vaccine in seronegative volunteers. Lancet. 1989 May 13;1(8646):1039–1041. doi: 10.1016/s0140-6736(89)92443-4. [DOI] [PubMed] [Google Scholar]
  7. Flehmig B., Ranke M., Berthold H., Gerth H. J. A solid-phase radioimmunoassay for detection of IgM antibodies to hepatitis A virus. J Infect Dis. 1979 Aug;140(2):169–175. doi: 10.1093/infdis/140.2.169. [DOI] [PubMed] [Google Scholar]
  8. Gauss-Müller V., Deinhardt F. Immunoreactivity of human and rabbit antisera to hepatitis A virus. J Med Virol. 1988 Feb;24(2):219–228. doi: 10.1002/jmv.1890240212. [DOI] [PubMed] [Google Scholar]
  9. Heinricy U., Stierhof Y. D., Pfisterer M., Flehmig B. Properties of a hepatitis A virus candidate vaccine strain. J Gen Virol. 1987 Sep;68(Pt 9):2487–2493. doi: 10.1099/0022-1317-68-9-2487. [DOI] [PubMed] [Google Scholar]
  10. Hughes J. V., Stanton L. W. Isolation and immunizations with hepatitis A viral structural proteins: induction of antiprotein, antiviral, and neutralizing responses. J Virol. 1985 Aug;55(2):395–401. doi: 10.1128/jvi.55.2.395-401.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hughes J. V., Stanton L. W., Tomassini J. E., Long W. J., Scolnick E. M. Neutralizing monoclonal antibodies to hepatitis A virus: partial localization of a neutralizing antigenic site. J Virol. 1984 Nov;52(2):465–473. doi: 10.1128/jvi.52.2.465-473.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  13. Lemon S. M., Barclay W., Ferguson M., Murphy P., Jing L., Burke K., Wood D., Katrak K., Sangar D., Minor P. D. Immunogenicity and antigenicity of chimeric picornaviruses which express hepatitis A virus (HAV) peptide sequences: evidence for a neutralization domain near the amino terminus of VP1 of HAV. Virology. 1992 May;188(1):285–295. doi: 10.1016/0042-6822(92)90758-h. [DOI] [PubMed] [Google Scholar]
  14. Milich D. R., Hughes J. L., McLachlan A., Thornton G. B., Moriarty A. Hepatitis B synthetic immunogen comprised of nucleocapsid T-cell sites and an envelope B-cell epitope. Proc Natl Acad Sci U S A. 1988 Mar;85(5):1610–1614. doi: 10.1073/pnas.85.5.1610. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Ping L. H., Jansen R. W., Stapleton J. T., Cohen J. I., Lemon S. M. Identification of an immunodominant antigenic site involving the capsid protein VP3 of hepatitis A virus. Proc Natl Acad Sci U S A. 1988 Nov;85(21):8281–8285. doi: 10.1073/pnas.85.21.8281. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Robertson B. H., Jia X. Y., Tian H., Margolis H. S., Summers D. F., Ehrenfeld E. Antibody response to nonstructural proteins of hepatitis A virus following infection. J Med Virol. 1993 May;40(1):76–82. doi: 10.1002/jmv.1890400115. [DOI] [PubMed] [Google Scholar]
  17. Updike W. S., Tesar M., Ehrenfeld E. Detection of hepatitis A virus proteins in infected BS-C-1 cells. Virology. 1991 Nov;185(1):411–418. doi: 10.1016/0042-6822(91)90789-e. [DOI] [PubMed] [Google Scholar]
  18. Wang C. H., Tschen S. Y., Flehmig B. Antigenicity of hepatitis A virus after ultra-violet inactivation. Vaccine. 1995 Jun;13(9):835–840. doi: 10.1016/0264-410x(94)00054-q. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES